Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy

Korean Journal of Internal Medicine

Volumn 31, Issue 5, 2016, Pages 961-970

  Kim, Tark ^a,b   Lee, Yu Mi ^b,c   Lee, Sang Oh ^b   Choi, Sang Ho ^b   Kim, Yang Soo ^b   Woo, Jun Hee ^b   Sung, Heungsup ^b   Jung, Joo Hee ^b   Shin, Sung ^b   Kim, Young Hoon ^b   Kang, Young Ah ^b   Lee, Young Shin ^b   Lee, Jung Hee ^b   Lee, Je Hwan ^b   Lee, Kyoo Hyung ^b   Park, Su Kil ^b   Han, Duck Jong ^b   Kim, Sung Han ^b  

^a Soonchunhyang University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

Cytomegalovirus; Hematopoietic stem cell transplantation; Kidney transplantation; Prophylaxis

Indexed keywords

GANCICLOVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PREEMPTIVE THERAPY; PROSPECTIVE STUDY; THERAPY; ADVERSE EFFECTS; COHORT ANALYSIS; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTIONS; GASTROENTERITIS; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION; SOUTH KOREA;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS RETINITIS; FEMALE; GANCICLOVIR; GASTROENTERITIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REPUBLIC OF KOREA; RISK FACTORS; SECONDARY PREVENTION;

EID: 84986905081     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2015.079     Document Type: Article

References (29)

1. Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:93-106.
2. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wing-ard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-558.
3. Le Page AK, Jager MM, Kotton CN, Simoons-Smit A, Rawlinson WD. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation 2013;95:1455-1460.
4. Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000;26:763-767.
5. Han JS, Lee SJ, Park WK, Ko YW, Kim HO, Lee SY. A survey on the cytomegalovirus antibodies in blood donors and the diseased. Korean J Blood Transfus 1990;1:21-34.
6. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6:2134-2143.
7. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008;8:69-77.
8. Jung GO, Kim SJ, Choi GS, et al. The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation. Transplant Proc 2010;42:804-810.
9. Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:1687-1699.
10. Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:431-434.
11. Burns LJ, Miller W, Kandaswamy C, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 2002;30:945-951.
12. Schetelig J, Oswald O, Steuer N, et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003;32:695-701.
13. Ozdemir E, St John LS, Gillespie G, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002;100:3690-3697.
14. Hambach L, Stadler M, Dammann E, Ganser A, Herten-stein B. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 2002;29:903-906.
15. Ko GB, Kim T, Kim SH, et al. Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation. Transpl Infect Dis 2013;15:416-423.
16. Kim T, Sung H, Park KT, et al. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation. Infect Chemother 2009;41:72-77.
17. Park SY, Lee SO, Choi SH, et al. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study. J Antimicrob Chemother 2012;67:1486-1492.
18. Jang EY, Park SY, Lee EJ, et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis 2009;48:e121-e124.
19. Moon SM, Sung H, Kim MN, et al. Diagnostic yield of the cytomegalovirus (CMV) antigenemia assay and clinical features in solid organ transplant recipients and hematopoietic stem cell transplant recipients with CMV pneumonia. Transpl Infect Dis 2012;14:192-197.
20. Couzi L, Helou S, Bachelet T, et al. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction. Transplant Proc 2012;44:2809-2813.
21. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother 2013;45:260-271.
22. Greiner M, Cusini A, Ruesch M, et al. A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. Infection 2012;40:669-675.
23. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CM-V)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-1979.
24. Tey SK, Kennedy GA, Cromer D, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One 2013;8:e74744.
25. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012;55:1678-1689.
26. Durand CM, Marr KA, Arnold CA, et al. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. Clin Infect Dis 2013;57:1550-1559.
27. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988;108:585-594.
28. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996 124:633-642.
29. Cariani E, Pollara CP, Valloncini B, Perandin F, Bonfanti C, Manca N. Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for human cytomegalovirus (HCMV) management in immunocompromised patients. BMC Infect Dis 2007;7:138.